Combined Intrathecal Dexmedetomidine and Adductor Canal Block for Analgesia After Total Knee Arthroplasty
Combined Intrathecal Dexmedetomidine and Adductor Canal Block for Analgesia After Total Knee Arthroplasty: A Randomized Controlled Trial
Kafrelsheikh University
75 participants
Feb 20, 2025
INTERVENTIONAL
Conditions
Summary
The aim of this work is to evaluate the effect of combined intrathecal dexmedetomidine and adductor canal block for analgesia after total knee arthroplasty (TKA).
Eligibility
Inclusion Criteria4
- Age from 18 to 75 years.
- Both sexes.
- American Society of Anesthesiology (ASA) physical status I-II.
- Scheduled for total knee arthroplasty under spinal anesthesia.
Exclusion Criteria7
- Patients with neurological or intellectual disability.
- History of allergy to local anesthetics or dexmedetomidine .
- Infection at the injection site.
- Prolonged use of analgesic or sedative medications.
- Coagulation abnormalities.
- Pregnancy.
- Obesity \[body mass index (BMI) \> 30 kg/m2\].
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 5 μg in 0.5ml dexmedetomidine + adductor canal block using 20 ml saline 0.9% at the end of surgery
Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 0.5ml saline 0.9% + adductor canal block using 20 ml bupivacaine 0.25% at the end of surgery.
Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 5 μg in 0.5ml dexmedetomidine + adductor canal block using 20 ml bupivacaine 0.25% at the end of surgery.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06837844